Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study

Botticelli investigators, the writing … - … of Thrombosis and …, 2008 - Wiley Online Library
Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …

Apixaban for extended treatment of venous thromboembolism

G Agnelli, HR Buller, A Cohen, M Curto… - … England Journal of …, 2013 - Mass Medical Soc
Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Oral apixaban for the treatment of acute venous thromboembolism

G Agnelli, HR Buller, A Cohen, M Curto… - … England Journal of …, 2013 - Mass Medical Soc
Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

The role of factor Xa inhibitors in venous thromboembolism treatment

KP Cabral, JE Ansell - Vascular Health and Risk Management, 2015 - Taylor & Francis
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism,
both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban …

Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)

M Nakamura, M Nishikawa, I Komuro, I Kitajima… - Circulation …, 2015 - jstage.jst.go.jp
Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …

Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose

TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - Wiley Online Library
A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

C Frost, Y Song, YC Barrett, J Wang… - Clinical …, 2014 - Taylor & Francis
Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - Taylor & Francis
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

[HTML][HTML] Apixaban: a clinical pharmacokinetic and pharmacodynamic review

W Byon, S Garonzik, RA Boyd, CE Frost - Clinical pharmacokinetics, 2019 - Springer
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

YC Barrett, J Wang, Y Song, J Pursley… - Thrombosis and …, 2012 - thieme-connect.com
Following major orthopaedic surgery, guidelines usually recommend continued
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …